|
|
||||||||||
|
J Am Coll Cardiol, 2005; 45:82-86, doi:10.1016/j.jacc.2004.09.045 © 2005 by the American College of Cardiology Foundation |
Cardiac Arrhythmia Service and Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts
Manuscript received June 8, 2004; revised manuscript received August 25, 2004, accepted September 2, 2004.
* Reprint requests and correspondence: Dr. Calum A. MacRae, Cardiovascular Research Center, Massachusetts General Hospital, 149 13th Street, Charlestown, Massachusetts 02129 (Email: cmacrae{at}partners.org).
OBJECTIVES: We sought to characterize natriuretic peptide levels in a cohort of rigorously characterized subjects with lone atrial fibrillation (AF).
BACKGROUND: Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are sensitive biomarkers of cardiac contractile dysfunction. Both peptides have been reported to be elevated in cohorts with AF, but previous studies have included subjects with underlying structural heart disease. We studied these hormones in 150 subjects with lone AF.
METHODS: Study subjects had electrocardiographic evidence of at least one episode of AF and a structurally normal heart on echocardiography. Subjects were excluded if they had a history of a myocardial infarction, rheumatic heart disease, cardiomyopathy, significant valvular disease, hyperthyroidism, or hypertension that preceded the onset of AF. Control subjects were obtained from a healthy outpatient primary care population. Plasma pro-ANP and N-terminal pro-BNP (nt-pro-BNP) levels were determined using commercially available immunoassays.
RESULTS: A total of 150 serial subjects with lone AF were enrolled and studied, the majority during normal sinus rhythm. Median levels of nt-pro-BNP were significantly elevated in subjects with lone AF as compared with control subjects (166 vs. 133 fmol/ml, p = 0.0003). There was no significant difference in pro-ANP levels between subjects with lone AF and control subjects (1,730 vs. 1,625 fmol/ml, p = 0.90).
CONCLUSIONS: Discordant natriuretic peptide levels were observed in this homogeneous population of subjects with lone AF. This biomarker pattern, which is present even in sinus rhythm, may represent an underlying subclinical predisposition to this common arrhythmia.
| ||||||
This article has been cited by other articles:
![]() |
K. Winkler, C. Wanner, C. Drechsler, J. Lilienthal, W. Marz, V. Krane, and for the German Diabetes and Dialysis Study Investi Change in N-terminal-pro-B-type-natriuretic-peptide and the risk of sudden death, stroke, myocardial infarction, and all-cause mortality in diabetic dialysis patients Eur. Heart J., September 1, 2008; 29(17): 2092 - 2099. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Darbar, A. Hardy, J. L. Haines, and D. M. Roden Prolonged signal-averaged P-wave duration as an intermediate phenotype for familial atrial fibrillation. J. Am. Coll. Cardiol., March 18, 2008; 51(11): 1083 - 1089. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. B. Daniels and A. S. Maisel Natriuretic Peptides J. Am. Coll. Cardiol., December 18, 2007; 50(25): 2357 - 2368. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Cardinale, A. Colombo, M. T. Sandri, G. Lamantia, N. Colombo, M. Civelli, M. Salvatici, G. Veronesi, F. Veglia, C. Fiorentini, et al. Increased Perioperative N-Terminal Pro-B-Type Natriuretic Peptide Levels Predict Atrial Fibrillation After Thoracic Surgery for Lung Cancer Circulation, March 20, 2007; 115(11): 1339 - 1344. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Rienstra, I. C. Van Gelder, M. P. Van den Berg, and D. J. Van Veldhuisen Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: determinants and prognostic value of (NT-)ANP and (NT-pro)BNP: reply Europace, February 1, 2007; 9(2): 148 - 148. [Full Text] [PDF] |
||||
![]() |
T Date, T Yamane, K Inada, S Matsuo, S Miyanaga, K Sugimoto, K Shibayama, I Taniguchi, and S Mochizuki Plasma brain natriuretic peptide concentrations in patients undergoing pulmonary vein isolation Heart, November 1, 2006; 92(11): 1623 - 1627. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Goetze, L. Friis-Hansen, J. F. Rehfeld, B. Nilsson, and J. H. Svendsen Atrial secretion of B-type natriuretic peptide Eur. Heart J., July 2, 2006; 27(14): 1648 - 1650. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Rienstra, I. C. Van Gelder, M. P. Van den Berg, F. Boomsma, and D. J. Van Veldhuisen Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: determinants and prognostic value of (NT-)ANP and (NT-pro)BNP Europace, July 1, 2006; 8(7): 482 - 487. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Laukkanen, S. Kurl, M. Ala-Kopsala, O. Vuolteenaho, H. Ruskoaho, K. Nyyssonen, and J. T. Salonen Plasma N-terminal fragments of natriuretic propeptides predict the risk of cardiovascular events and mortality in middle-aged men Eur. Heart J., May 2, 2006; 27(10): 1230 - 1237. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. T. Ellinor, A. F. Low, and C. A. MacRae Reduced apelin levels in lone atrial fibrillation Eur. Heart J., January 2, 2006; 27(2): 222 - 226. [Abstract] [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |